骨科

订阅

MedSci主页 / 所有栏目 / 骨科

Int J Nanomed：ERK1/2通路在辛伐他汀负载纳米胶束和辛伐他汀调节MG63细胞成骨作用中的作用

2018-12-29 MedSci MedSci原创

关注

本研究旨在探究ERK1/2通路在负载辛伐他汀（SV）的纳米胶束（SVNs）和SV介导的促进细胞的成骨分化过程中的作用，并探究SVNs在促进成骨分化方面比SV具有更大功效的分子机制。使用透析方法合成SVNs。使用2.5,0.25和0.025μmol/L的药物处理MG63细胞。通过检查MG63细胞的增殖活性和ALP活性来确定最佳药物剂量。随后，使用Western印迹分析以分析每个实验组中在不同时间点的

本研究旨在探究ERK1/2通路在负载辛伐他汀（SV）的纳米胶束（SVNs）和SV介导的促进细胞的成骨分化过程中的作用，并探究SVNs在促进成骨分化方面比SV具有更大功效的分子机制。

使用透析方法合成SVNs。使用2.5,0.25和0.025μmol/L的药物处理MG63细胞。通过检查MG63细胞的增殖活性和ALP活性来确定最佳药物剂量。随后，使用Western印迹分析以分析每个实验组中在不同时间点的磷酸化ERK1/2蛋白的水平。最后，使用抑制剂PD98059抑制ERK1/2通路。分析了MG63细胞和成骨相关标志物的增殖活性的变化。

结果显示，本研究合成的SVNs的平均直径为27nm。包封率和载药效率分别为52.03％±4.05％和9.42％±0.66％。当药物以0.25μmol/L的浓度给药时，SVNs和SV表现出最佳的促骨生成作用。药物诱导的ERK1/2通路激活在给药后15分钟达到峰值，然后迅速下降。从24小时到7天，SVN和SV对ERK1/2通路发挥抑制作用而不是激活作用。在整个实验过程中，SVNs对ERK1/2通路的调节作用明显大于SV。PD98059对ERK1/2通路的抑制显著降低了所有实验组中细胞的增殖活性。此外，ALP活性和osterix（OSX）和骨钙蛋白（OC）蛋白的表达水平明显增加。

综上所述，该研究结果表明，SVN通过强抑制ERK1/2通路显著增加SV诱导的成骨分化的作用。

原始出处：

Niu M, Feng X, Zhou L. The role of the ERK1/2 pathway in simvastatin-loaded nanomicelles and simvastatin in regulating the osteogenic effect in MG63 cells. Int J Nanomedicine. 2018 Dec 5;13:8165-8178. doi: 10.2147/IJN.S182998. eCollection 2018.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752118, encodeId=14f91e5211806, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sun Mar 31 06:02:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351936, encodeId=5b7e1351936fb, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368103, encodeId=26711368103d4, content=<a href='/topic/show?id=f2fd938442c' target=_blank style='color:#2F92EE;'>#辛伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93844, encryptionId=f2fd938442c, topicName=辛伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609432, encodeId=4827160943271, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356652, encodeId=3f69356652f0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Dec 29 07:10:35 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2019-03-31 chenlianhui

    #ERK#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1752118, encodeId=14f91e5211806, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sun Mar 31 06:02:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351936, encodeId=5b7e1351936fb, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368103, encodeId=26711368103d4, content=<a href='/topic/show?id=f2fd938442c' target=_blank style='color:#2F92EE;'>#辛伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93844, encryptionId=f2fd938442c, topicName=辛伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609432, encodeId=4827160943271, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356652, encodeId=3f69356652f0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Dec 29 07:10:35 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2018-12-30 zhaojie88

    #成骨#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1752118, encodeId=14f91e5211806, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sun Mar 31 06:02:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351936, encodeId=5b7e1351936fb, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368103, encodeId=26711368103d4, content=<a href='/topic/show?id=f2fd938442c' target=_blank style='color:#2F92EE;'>#辛伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93844, encryptionId=f2fd938442c, topicName=辛伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609432, encodeId=4827160943271, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356652, encodeId=3f69356652f0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Dec 29 07:10:35 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2018-12-30 zhangmingxiang

    #辛伐他汀#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1752118, encodeId=14f91e5211806, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sun Mar 31 06:02:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351936, encodeId=5b7e1351936fb, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368103, encodeId=26711368103d4, content=<a href='/topic/show?id=f2fd938442c' target=_blank style='color:#2F92EE;'>#辛伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93844, encryptionId=f2fd938442c, topicName=辛伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609432, encodeId=4827160943271, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356652, encodeId=3f69356652f0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Dec 29 07:10:35 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2018-12-30 ms3994565386320060

    #Med#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1752118, encodeId=14f91e5211806, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sun Mar 31 06:02:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351936, encodeId=5b7e1351936fb, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368103, encodeId=26711368103d4, content=<a href='/topic/show?id=f2fd938442c' target=_blank style='color:#2F92EE;'>#辛伐他汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93844, encryptionId=f2fd938442c, topicName=辛伐他汀)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609432, encodeId=4827160943271, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 17:02:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356652, encodeId=3f69356652f0, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Dec 29 07:10:35 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2018-12-29 1e1c07bdm01(暂无匿称)

    好

    0